Navigation Links
STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
Date:1/19/2009

to registration in the USA.

About The Oralair Development Program

According to World Health Organization (WHO) estimates, 20 to 25% of the world's population suffer from respiratory allergic symptoms (rhinitis and/or asthma). By 2020, 50% of the world's population will be affected by allergy according to the ISAAC study. According to WHO, desensitization is the only treatment that addresses the immunological cause of allergy and modifies the natural course of the disease. Nearly 15 to 20% of these patients suffer from moderate to severe allergic rhinitis and rhinoconjunctivitis, not controlled by their usual medical treatment.

Since 2003, Stallergenes has been running the Oralair program, which addresses these unmet medical needs with EBM-documented, registered allergen tablets that are safe and easy-to-use.

This program consists in the development of tablets for four of the main allergens triggering more than 80% of these allergies: grass pollens, house dust mites, birch pollen and ragweed pollen.

The entire program is in the clinical development stage and is proceeding according to schedule.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 20% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had a turnover of 170,9 million euros and provided desensitization treatments to more than 500,000 patients.

Stallergenes is listed on Euronext Paris (Compartment B and is part of the sample composing the SBF 120 index.

'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
2. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
3. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
4. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
7. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
8. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
9. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
10. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
11. Curemark Appoints Preeminent Pediatrics Gastroenterologist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59%... -- BEIJING, Aug. 16 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets -- LAIYANG, China, Aug. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // ...
Cached Medicine Technology:Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 2Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 3Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 4Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 5Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 6Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 7Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 8Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 9Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 10Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 11Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 12Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 2Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 3Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 4Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 5Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 6Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 7
(Date:12/26/2014)... 2014 Cooking and warming equipment ... of 5. This score reflects slightly positive negotiation conditions ... specialization, low switching costs and a low level of ... low availability of substitutes for cooking and warming equipment ... and aluminum, key inputs in the production process of ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... Against the backdrop of last week,s Congressional hearing into ... at Buffalo,s Laboratory for Forensic Odontology Research in the ... on the controversial topic of bitemark analysis. The Congressional ... of Sciences (NAS) report on the scientific basis of ...
... Sept. 16 Managed Health Care Associates, Inc. (MHA), ... the country, today announced the immediate availability of RxPertise ... Regimen Review (MRR) software for consultant pharmacists in the ... efficiently manage the utilization, outcomes, and reporting requirements for ...
... abuse among undergrads, study shows , WEDNESDAY, Sept. 16 ... among university students, but an Internet-based intervention may help ... , Researchers analyzed data from a Web-based alcohol-use screening ... aged 17 to 24, in Australia, and found that ...
... The most important voice is YOURS! ... The Pennsylvania Breast Cancer Coalition (PBCC) Annual Conference will be held on ... 8:30 a.m. to 3:30 p.m. , , ... Pennsylvania Breast Cancer Coalition Annual Conference is the only statewide breast cancer ...
... , , , ... California hospital industry, El Camino Hospital CEO, Ken Graham, will provide insight ... Healthcare CEO Summit on Sept. 17 at 7:15 a.m. at the Rotary ... leadership, Graham has much to contribute to the health care reform debate. ...
... www.intelligenthospitals.com , , WINNIPEG, Sept. 16 ... pharmacy across North America, 77% of those looking to ... Intravenous Automation) - a self-contained unit for filling IV ... - as a vendor under consideration. The survey was ...
Cached Medicine News:Health News:Bitemark evidence and analysis should be approached with caution, according to UB study 2Health News:Bitemark evidence and analysis should be approached with caution, according to UB study 3Health News:MHA Announces Release of RxPertise(TM) 8.0 2Health News:Internet Can Help Curb Drinking Among College Students 2Health News:Pennsylvania Breast Cancer Coalition Hosts Annual Conference 2Health News:El Camino Hospital Provides Local Perspective on Health Care Reform and Innovation at Silicon Valley Healthcare CEO Summit 2Health News:IH Systems RIVA Top Pick for Directors of Pharmacy 2
... The ABI Prism 7000 Sequence ... PCR system that detects and quantitates ... cycle-by-cycle detection of accumulated PCR product ... cycling, fluorescence detection, and application-specific software ...
RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum [with calibrators]....
ELISA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum....
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
Medicine Products: